Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, combined with CHP (cyclophosphamide, doxorubicin, prednisone), demonstrates superior efficacy in CD30 + lymphomas, with a 68% CR rate and estimated median survival exceeding 24 months in the ECHELON-2 trial, while avoiding vincristine-related neurotoxicity [15–17]. This evidence concerns the gene TNFRSF8 and lymphoma.